Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL4206831 | 0.92 | TP53 (0.46) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143574 | 0.92 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143494 | 0.91 | PDE4B (0.60) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143654 | 0.91 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143737 | 0.91 | TP53 (0.44) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143358 | 0.91 | PDE4B (0.49) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143845 | 0.89 | TP53 (0.47) | PDE4APDE4BPDE4CPDE4DTP53 | |
| SCHEMBL1143797 | 0.87 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DTP53 | |
| Cyclopropane SCHEMBL4211055 | 0.85 | MEN1 (0.41) | TP53MEN1KMT2AMAPT | |
| SCHEMBL1144026 | 0.84 | PDE4B (0.70) | PDE4APDE4BPDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | claimed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | claimed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | claimed |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-10-14 | — | — | US | claimed |
| US-8263637-B2 | Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158672-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2011-05-26 | — | — | US | disclosed |
| EP-1587474-A3 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-09-15 | — | — | EP | disclosed |
| US-20050148034-A1 | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds | Celularity, Inc. | 2005-07-07 | — | — | US | disclosed |
| US-20050118715-A1 | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | Celularity, Inc. | 2005-06-02 | — | — | US | disclosed |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-2004060313-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060313-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | IL2, IL6, IL1B | PDE4A 295/4885PDE4B 348/4885PDE4C 352/4885 |
| US-20110124645-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4A 1843/4885PDE4B 1724/4885PDE4C 1641/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4A 498/4885PDE4B 561/4885PDE4C 612/4885 |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20050118715-A1 | Modulation of stem and progenitor cell differentiation, assays, and uses thereof | PGF, MYADM, ALPP | PDE4A 1010/4885PDE4B 992/4885PDE4C 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.